

REFERENCES

(A)

1) Ahdout, J. ; Kim, J. and Chiu, M.(2009):

Modifiable metabolic syndrome associated lifestyle factors in psoriasis patients.

J. Am .Acad .Dermatol. ; 60 :165-169.

2) Akhyani, M.; Ehsani, A.H.; Robati, R.M. and Robati, A.M . (2007) :

The lipid profile in psoriasis: a controlled study.

J. Eur .Acad .Dermatol .Venereol.; 21(10):1330-1332.

3) Andrea, L.; Neimann, T.; Daniel, B.; Shin B.A.; Wang, X.; David, J.; Margolis,

R.; Andrea, B.; Troxel, N. ; Joel, M. and Gelfand, M. (2006):

Prevalence of cardiovascular risk factors in patients with psoriasis.

J. Am. Acad .Dermatol.; 52 :23-26.

4) Andrea, L.N.; Steven, B.P. and Joel, M.G. (2006):

The epidemiology of psoriasis.

Expert Rev. Dermatol.; 1 : 63-75.

5) Andreas, F.; Ralph, D.J.; George, H.; Leena, M. ; Russell , P.T. and Steven,

M.H. (2000):

Chronic subclinical inflammation as part of the insulin resistance syndrome.

Circulation; 102 : 42-44.

6) Aringer, M.(2002):

T lymphocyte activation-an inside overview.

Acta .Med. Austriaca. ; 29: 7-13.

7) Ascaso, J.F.; Lorente, R. and Merchante , A.(1997):

Insulin resistance in patients with familial combined hyperlipidemia and ischemic heart disease.

Am . J. Cardiol .;80:1484–1487.

8) Avci, O.; Caliskan, S. and Caliskan, M. (2003):

Erythema measurements may allow early diagnosis of diabetes mellitus in adult psoriatics.

J .Eur. Acad .Dermatol .Venereol.; 17: 280-284.

(B)

9) Bajaj, D.R.; Mahesar, S.M.; Devrajani, B. and Iqbal ,M.P .(2009):

Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad .

J. Pak .Med. Assoc.; 59 : 512-515.

10) Barker,L. (2001):

Genetic aspects of psoriasis.

Clinical and Experimental Dermatology ; 26 : 321– 325.

11) Basavaraj, M.S.; Darshan, P. ; Shanmugavelu, R. ;Rashmi, A. ;Yuti-Mhatre, S.P. and Dhanabal, K.S.J. (2009):

Study on the levels of trace elements in mild and severe psoriasis.

Clinica. Chimica. Acta .; 405: 66-70.

12) Becker, N.; Deeg, E.; Rudiger ,T. and Nieters, A.(2005):

Medical history and risk for lymphoma: results of a population-based case-control study in Germany.

Eur. J. Cancer; 41:133-142.

13) Becker, K.G.; Simon, R.M.; Bailey-Wilson, J.E.; Freidlin, B. and Biddison, W.E. (1998):

Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases.

Proc. Nat. Acad. Sci .USA ; 95: 9979-9984.

14) Benko, M. (2007):

Functional Data Analysis.

In: Härdle, W.; Mori, Y. and Vieu, P. (eds.): Statistical Methods for Biostatistics and Related Fields, 1st edition.

Springer-Verlag Berlin Heidelberg Press, Ch. 16, PP. 305-327.

15) Boehncke, S.; Thaci, D.; Beschmann, H.; Ludwig, R.J.; Ackermann, H.; Badenhoop, K. and Boehncke, W.H. (2007):

Psoriasis patients show signs of insulin resistance.

British J. of Dermatology ; 157:1249-1251.

16) Boehncke, W.H. and Boehncke, S. (2008 a):

Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences.

J. Ital .Dermatol .Venereol. ;143: 307-313.

17) Boehncke, W.H. and Boehncke, S. (2008 b):

Research in practice: the systemic aspects of psoriasis.

J .Dtsch. Dermatol .Ges.; 6:622-625.

18) Boehncke W.H.; Boehncke, S. and Buerger, C. (2009):

Co-morbidities in psoriasis vulgaris

Hautarzt.; 60:116-121.

19) Boffetta, P.;Gridley ,G. and Lindelof, B. (2001):

Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden.

J. Invest. Dermatol.; 117:1531-1537.

20) Bowcock ,A.M. and Barker, J.N. (2003):

Genetics of psoriasis: the potential impact on new therapies.

J. Am. Acad. Dermatol.; 49: 51-56.

21) Bowcock, A.M .and Krueger, J.G.(2005):

Getting under the skin: the immunogenetics of psoriasis.

Nat. Rev. Immunol.; 5: 699 –711.

22) Brauchli Y.B; Jick S.S .and Meier C.R.(2008):

Psoriasis and the risk of incident diabetes mellitus: a population-based study

Br. J. Dermatol.;159: 1331-1337.

23) Buchanan, T.A.; Xiang A.H.; Peters, R.K.; Kjos, S.L.; Marroquin ,A. and Goico, J. (2002):

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

Diabetes; 51: 2796-2803.

24) Buske-Kirschbaum, A.; Kern, S.; Ebrecht, M. and Hellhammer, D.H. (2007):

Altered distribution of leukocyte subsets and cytokine production in response to acute psychosocial stress in patients with psoriasis vulgaris.

Brain Behav. Immun.; 21: 92-99.

(C)

25) Campbell, M.J. (2003):

Confidence intervals. In: Campbell, M.J. (ed.): Statistics at square two: understanding modern statistical applications in medicine, 1st edition.

BMJ Publishing Group Press, Ch. 1, PP. 6.

26) Capes, S. and Anand, S. (2001):

What is type 2 diabetes?

In: Evidence based diabetes care.

Gerstein HC, Haynes RB (eds.); Hamilton, Ont, Decker; pp: 151 -163.

27) Carneiro, S.; Pereira, N.; Gustavo, A.; Verardino, D.; Brollo, M. and Ramos, M. (2009):

Lipid profile of psoriasis patients of a Brazilian university hospital

J. Am. Acad. Dermatol. ; 60:169-173.

28) Chan, J.R.; Blumenschein, W.; Murphy, E.; Diveu C.; Wiekowski, M.; Abbondanzo, S. (2006):

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.

J. Exp. Med. ; 203: 2577–2587.

29) Chen, C.; Chen, Y.; Lee, F.; Shen, J.; Wu, C. and Chang, Y. (2008):

Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis

J. Am. Acad. Dermatol.; 60:225-230.

30) Christophers ,E. (2007):

Co-morbidities in psoriasis.

Clin. Dermatol. ; 25: 529-534.

31) Coggon, D. (2003):

Summarising univariate data.

In: Coggon, D (eds.): Statistics in Clinical Practice, 2nd edition.

BMJ Publishing Group Press, Ch. 2, PP. 27-46.

32) Cohen, A.D.; Gilutz ,H.; Henkin Y.; Zahger, D.; Shapiro, J.; Bonne, D.Y. and Vardy, D.A. (2007):

Psoriasis and the metabolic syndrome.

Acta. Derm. Venereol.; 87: 506-509.

33) Cohen, A.D.; Sherf, M.; Vidavsky, L.; Vardy D.A.; Shapiro, J. and Meyerovitch, J. (2008):

Association between psoriasis and the metabolic syndrome: A cross-sectional study.

Dermatology; 16:152-155.

(D)

34) Danesh, J.; Wheeler, J.G.; Hirschfield, G.M.; Eda,S.; Eiriksdottir, G .and Rumley, A.(2004):

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

N .Engl.J. Med.;350:1387-1397.

35) Diwan, A.; Tran, T.; Misra, A. and Mann, D.L. (2003):

Inflammatory mediators and the failing heart: a translational approach.
Curr. Mol. Med.; 3: 161-182.

36) Drateln, C.R.; Esperanza, M.A.; Blanca, R.; Rafael, B.S. and Manuel G.O. (2003):

Lipid profile, insulin secretion, and insulin sensitivity in psoriasis.
J .Am. Acad. Dermatol.; 48: 882-885.

37) Dreiherr, J.; Cohen, A.D.; Shapiro, Y.; Vidavsky, L.; Vardy, D.A.; Davidovici, B. and Meyerovitch, J. (2008):

Psoriasis and diabetes: a population-based cross-sectional study.
J .Eur .Acad. Dermatol .Venereol.; 22: 585-589.

(E)

38) Elder, J.T.; Henseler, T.; Christophers, E.; Voorhees, J.J. and Nair, R.P. (1994):

Of genes and antigens the inheritance of psoriasis.
J. Invest. Dermatol. ; 103: 150-153.

39) Ermertcan, T. A.; Temeltas, G.; Deveci, A.; Dinç, G.; Güler, H.B. and Oztürkcan, S. (2006):

Sexual dysfunction in patients with psoriasis.
J. Dermatol. ; 33: 772-778.

40) Esposito, K.; Giugliano, F. ; D'Armiento, M. and Giugliano, D. (2008):

Obesity and sexual dysfunction, male and female.
International Journal of Impotence Research ;20: 358–365.

(F)

41) Feelter , M.; Foley, F. and Matthew, A . (2009):

Developments in psoriasis and psoriatic arthritis
Drug Discovery Today: Disease Mechanisms; 5: 47-54.

42) Fernandez-Real, J.M. and Ricart, W. (2003):

Insulin resistance and chronic cardiovascular inflammatory syndrome.
Endocr. Rev. ; 24 :278–301.

43) Fernandez-Real, J.M.; Vayreda, M.; Richart, C.; Gutierrez, C.; Broch ,M.; Vendrell ,J. and Richart, W. (2001):

Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.
J. Clin .Endocrinol. Metab. ; 86:1154-1159.

44) Field, S.; Kelly, G.; Tobi, A.M.; Barragry, J.M.; Conlon, K.C. and Kirby, B. (2008):

Severe deterioration of psoriasis due to an insulinoma.
Clin. Exp .Dermatol. ; 3(2):145-147.

45) Forbes, C.D. and Jackson, W.F. (2003):

Obesity.
In: Color atlas and text of clinical medicine. In: Hardle, W.; Mori, Y. and Vieu, P. (eds.), 3rd edition.
Elsevier Science; p: 326-330.

46) Fraser ,A.D.; Van Kuijk, A.W. and Westhovens, R. (2005):

A randomized, double blind, placebo controlled multicentre trial of combination therapy with methotrexate plus cyclosporine in patients with active psoriatic arthritis.

Ann. Rheum .Dis.; 64: 859-864.

47) Fukuhara, A. (2005):

Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.

Science; 307: 426-430.

(G)

48) Gaspari, A.A. (2006):

Innate and adaptive immunity and the pathophysiology of psoriasis.

J. Am. Acad. Dermatol.; 54: 67-80.

49) Gawaz, M.; Langer, H. and May, A.E. (2005):

Platelets in inflammation and atherogenesis.

J. Clin. Invest.;115:3378-3384.

50) Gelfand, J.M.; Berlin, J.; Van Voorhees, A. and Margolis, D.J. (2003):

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

Arch .Dermatol.; 139:1425-1429.

51) Gelfand, J.M.; Neimann, A.L.; Shin, DB.;Wang, X.; Margolis, D.J. and Troxel, A.B.(2006):

Risk of myocardial infarction in patients with psoriasis.

JAMA.; 296: 1735-1741.

- 52) Gelfand, J.M.; Stern, R.S.; Nijsten, T.; Feldman, S.R.; Thomas, J.; Kist J.; Rolstad, T. and Margolis, D.J. (2005):**

The prevalence of psoriasis in African Americans: results from a population-based study.

J .Am.Acad. Dermatol. ; 52 : 23-26.

- 53) Gelfand, J.M.; Weinstein, R.;Porter, S.B.; Neimann, A.L.; Berlin, J.A. and Margolis, D.J. (2005):**

Prevalence and treatment of psoriasis in the United Kingdom: A population- based study.

Arch. Dermatol., 141: 1537- 1541.

- 54) Genuth, S.; Alberti ,K.G. ;Bennett, P.; Buse, J.; Defronzo, R. and Kahn, R. (2003):**

Follow-up report on the diagnosis of diabetes mellitus.

Diabetes Care ; 26: 3160-3167.

- 55) Gerald, R.; Fahim, A. And Tracey, M. (2007):**

Obesity, insulin resistance, and cardiovascular disease.

Rphr . Endo. journals Org. ;59 :207-223.

- 56) Ghoreschi, K.; Weigert ,C.and Röcken, M. (2007):**

Immunopathogenesis and role of T cells in psoriasis

Clinics in Dermatology ;25: 574–580.

- 57) Gilliet, M.; Conrad, C.; Geiges , M.; Cozzio, A.; Thürlimann, W. and Burg G. (2004) :**

Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.

Arch. Dermatol.;140:1490–1495.

58) Gilliet, M .and Lande, R.(2008) :

Antimicrobial peptides and self-DNA in autoimmune skin inflammation.
Curr. Opin .Immunol.; 20: 401–407.

59) Gisondi, P.; Giglio,M.; Francesco,V.; Zamboni, M. and Girolomoni ,G. (2008):

Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.
Am. J. Clin. Nutr.; 88: 1242–1247.

60) Gisondi, P. and Girolomoni ,G.(2009):

Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
Semin. Thromb .Hemost.; 35:257-259.

61) Gisondi, P.; Tessari, G.; Conti , A.; Piaserico, S.; Schianchi,S.; Peserico, A.; Giannetti , A. and Girolomoni ,G.(2007):

Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study.
Br .J .Dermatol.; 157: 68-73.

62) Godic, A. (2004):

New approaches to psoriasis treatment.
Acta .Derm.Venereol.; 13: 50-57.

63) Gonzalez-Ortiz,M.; Martinez-Abundis, E. and Lifshitz, A. (1998):

Insulin sensitivity and sex steroid hormone levels during the menstrual cycle in healthy women with non-insulin–dependent diabetic parents.
Gynecol .Obstet .Invest.; 46:187-190.

64) Goodman, M.; White, G.; McCormick, A. and Mc Cullough, J. (1992):

Cyclosporin therapy for psoriasis: a cell cycle-derived dosing schedule.
J.Am .Acad .Dermatol.; 27: 594-597.

65) Gottlieb, A.B.; Chao, C. and Dann, F. (2008):

Psoriasis co-morbidities.
J. Dermatol .Treat.; 19:5-21.

66) Gottlieb, A.B.; Dann, F. and Menter, A. (2008):

Psoriasis and the metabolic syndrome.
J.of drugs in Dermatology; 154: 250- 260.

67) Gottlieb, A.B. And Krueger, J.G. (1990):

HLA region genes and immune activation in the pathogenesis of psoriasis.
Arch. Dermatol.; 126: 1083-1086.

68) Goutham, R.A. (2001):

Insulin Resistance Syndrome.
Am. Fam .Physician; 63:1159-1166.

69) Griffiths, C.E.; Camp, R.D. and Barker, J.N. (2004):

Psoriasis. In: Rook`s textbook of Dermatology. Tony B, Stephen B, Neil C and Christopher G (eds). Seventh edition.
BlackWell science, Oxford, UK. Chapter 35; pp: 1-69.

70) Griffiths, C.E.; Christophers, E.; Barker, J.N.; Chalmers R.J.;Chimenti, S. and Krueger, G.G. (2007):

A classification of psoriasis vulgaris according to phenotype.
Br.J .Dermatol. ;156: 258- 262.

- 71) Griffiths, C.E.; Clark, C.M.; Chalmers, R.J.G.; Li -Van, P.A. and Williams, H.C. (2000):**
A systematic review of treatments for severe psoriasis.
Health Technol. Assess.; 4(40):1-125.
- 72) Grunbaum, J.A.; Kann, S. and Kinchen, S.A. (2005):**
Youth risk behavior surveillance.
United States MMWR Surveil . Summ . ; 51: 1. 62.
- 73) Grundy, S.M.; Brewer, H.B.; Cleeman, JI; Smith, S.C. and Lenfant, C. (2004):**
American Heart Association; National Heart, Lung and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung and Blood institute / American Heart Association conference on scientific issues related to definition.
Circulation ; 109: 433-438.
- 74) Grzybowski, G.; Fafara, I.; Zaba, R. and Wierusz-Wysocka, B.(2001):**
Evaluation of glucose, insulin, C-peptide uric acid serum levels in patients with psoriasis.
Pol. Merkur Lekarski ; 11:495-498.
- 75) Guenther, L.C. and Ortonne ,J.P. (2002):**
Pathophysiology of psoriasis: Science behind therapy.
J .Cut .Med. Surg.; 6:2-7.
- 76) Guido, C. ; Mrowietz,U.; Wolfart,M.; Patrick, H.; Warnke,K.; Wiltfang,J. and Springer ,N.G. (2009) :**
Psoriasis of the tongue
Journal of Cranio-Maxillofacial Surgery; 37: 51-53.

77) Gupta, G.; Gelfand, J.M. and Lewis, J.D. (2005):

Increased risk for demyelinating diseases in patients with inflammatory bowel disease.

Gastroenterology; 129: 819-826.

78) Gupta, M. A. and Gupta, A. K. (1997):

Psoriasis and sex: a study of moderately to severely affected patients.

International Journal of Dermatology; 36 : 259-262.

(H)

79) Hagforsen , E.; Michaëlsson, K; Lundgren, E.; Olofsson,H.; Petersson, A.; Lagumdzija A.; Hedstrand H. and Michaëlsson ,G. (2005):

Women with palmoplantar pustulosis have disturbed calcium homeostasis and a high prevalence of diabetes mellitus and psychiatric disorders: a case-control study.

Acta .Derm.Venereol.; 85: 225-232.

80) Hamminga, E.A.; Lely A.I.; Neumann, H.A.M. and Thio, H.B.(2006):

Chronic inflammation in psoriasis and obesity: implications for therapy.

Med . Hypotheses ; 67: 768-773.

81) Hannuksela, A.; Pukkala, E.; Laara ,E.; Poikolainen, K. and Karvonen, J. (2000):

Psoriasis, its treatment, and cancer in a cohort of Finnish patients.

J. Invest .Dermatol.; 114(3):587-590.

82) Hansson, G.K. and Libby, P. (2006):

The immune response in atherosclerosis: a double-edged sword.

Nat. Rev. Immunol.; 6 : 508-519.

83) Heidenreich,R.; Rocken, M.and Ghoreschi,K.(2009):

Angiogenesis drives psoriasis pathogenesis.

Int. J.Exp.Pathol.;90:232-348.

84) Henseler, T. (1997):

The genetics of psoriasis.

J. Am .Acad. Dermatol. ; 37:1-11.

85) Henseler, T. and Christophers, E. (1995):

Disease concomitance in psoriasis.

J.Am .Acad. Dermatol.; 32:982-986.

86) Hermenio, C.; Lima,F. ; Mulinari-Brenner,L.; Correia,G.; Kusano,L.and Flavia, S.(2009):

Prevalence of metabolic syndrome among patients with psoriasis at a dermatologic service in the south of Brazil.

J.Am .Acad .Dermatol.; 60: 166-167.

87) Herron, M.D.; Hinckley, M.; Hoffman, M.S.; Papenfuss J.; Hansen, C.B. and Callis, K.P. (2005):

Impact of obesity and smoking on psoriasis presentation and management.

Arch. Dermatol.; 141:1527-1534.

88) Higgins, E. (2005):

Alcohol, smoking and psoriasis.

Clin .Exp. Dermatol; 25:107-110.

(J)

- 89) *James, S.; Pankow, D.; David, R.; Jacobs, J.R.; Julia ,S.; Antoinette, M. and Alan, R.S. (2004):*

Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome.

Diabetes Care; 27:775-780.

- 90) *James, W.D.; Berger, T.G. and Elston, D.M. (2006):*

Seborrheic dermatitis, psoriasis, recalcitrant palmoplantar eruptions, pustular dermatitis, and erythroderma.

In: Andrew`s, Diseases of the skin, Clinical Dermatology. William DJ, Timothy GB and Dirk ME (eds.).Tenth edition. Elsevier, Canada. Chapter 10; pp:191-205.

- 90) *Jiang, W.Y.; Chattedee, A.D.; Raychaudhuri,S.P.; Raychaudhuri ,S.K. and Farber, E.M.(2001):*

Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int. J. Dermatol.; 40: 699-703.

- 91) *Jiaravuthisan M.M; Sasseville,D.; Ronald, B.; Murphy,F. and Channy, Y.(2007):*

Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy

J .Am. Acad. Dermatol . ; 57:1-27.

- 92) Jonathan, S.; Micheal, D.; Arnon, D.C.; Emilia, H.; Gabi, C.; Anna, V. and Anthony, H. (2007):**

The association between psoriasis, diabetes mellitus and atherosclerosis in Israel: A case-control study.

J .Am. Acad. Dermatol.; 56(4):629-634.

(K)

- 93) Kanaya, A.M .and Narayan, K.M. (2003):**

Prevention of type 2 diabetes: data from recent trials.

Prim. Care; 30:511-526.

- 94) Katz, H.I.; Waalen, J. and Leach, E.E. (1999):**

Acitretin in psoriasis: an overview of adverse effects.

J .Am .Acad. Dermatol.; 41:7-12.

- 95) Kelley, D.E. and Goodpaster, B.H. (2001):**

Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance.

Diabetes Care; 24:933-941.

- 96) Khan, A.H. and Pessin, J.E. (2002):**

Insulin regulation of glucose uptake: a complex interplay of intracellular signaling pathways.

Diabetologia; 45:1475-1483.

- 97) **Kimball , A.B.; Bruce ,E.; Gladman, D. ; Neil,E .J.; Gelfand,M.; Gordon, K.; Korman,L.; KorverG.; Krueger G.G. ; Strober, M. and Lebwohl M.G.(2008):**
National Psoriasis Foundation clinical consensus on psoriasis co - morbidities and recommendations for screening.
J. Am.Acad.Dermatol.;58: 1031-1042.
- 98) **Kimball, A.B. ; Guerin,A.; Mulani,P.; Park, A. and Gupta,S. (2009):**
The risk of coronary heart disease and stroke among psoriasis patients
J. Am. Acad. Dermatol. ; 60: 179-182.
- 99) **Kimball A.B.; Thomas, S. and Kupper, (2008)**
Future perspectives in psoriasis treatment? Immunology, pharmacogenomics, and epidemiology
Clinics in Dermatology ;26: 554–561.
- 100) **Kirby, B. and Griffiths, C.E. (2001):**
Psoriasis: the future.
Br .J .Dermatol. ; 58:37-43.
- 101) **Kohler, G.I.; Bode-Boger, S.M. and Busse, R. (2000):**
Drug–drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use.
Int .J. Clin. .Pharmacol..Ther.; 38:504-513.
- 102) **Kourosch, A.S.; Miner, A. and Menter, A. (2008):**
Psoriasis as the marker of underlying systemic disease.
Skin Therapy Lett.; 13: 1-5.

103) Krueger, J. G. and Ellis, C.N. (2005):

Psoriasis: recent advances in understanding its pathogenesis and treatment.
J .Am .Acad .Dermatol.; 53: 94-100.

104) Krueger, J.G.; Langely R.G.; Leonardi,C.; Yeilding , N.; Guzzo,C. and Wang ,Y.(2007):

A human interleukin 12/23 monoclonal antibody for the treatment of psoriasis.
N.Engl.J.Med.;356:580-592.

(L)

105) Lande, R . ;Gregorio , J.; Facchinetti, V.; Chatterjee, B.; Wang, Y.H. and Homey, B.(2007):

Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.
Nature ;449: 564–569.

106) Lentz ,S.R. ; Rodionova, R.N. and Dayal, S.(2003):

Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
Atherosclerosis Supplements; 4 :61–65.

107) Leong, T.T.; Fearon, U. and Veale, D.J. (2005):

Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis.
Curr .Rheumatol .Rep.; 7: 325-329.

108) Lindegard, B. (1986):

Diseases associated with psoriasis in a general population of 159, 200 middle-aged, urban, native Swedes.
Dermatologica.; 172:298-304.

109) Liu, Y.; Krueger, J.G. and Bowcock, A.M. (2007):

Psoriasis: genetic associations and immune system changes.
Genes Immun.; 8:1-12.

110) Lucas, D.L.; Brown, R.A.; Wassef, M. and Giles, T.D. (2005):

Alcohol and the cardiovascular system research challenges and opportunities.
J. Am .Coll .Cardiol.;45:1916-1924.

111) Ludwig, R.; Herzog, C.; Rostock, A.; Ochsendorf, F.R.; Zollner, T.M. and Thaci, D. (2007):

Psoriasis: a possible risk factor for development of coronary artery calcification.
Br .J .Dermatol. 156:271-276.

(M)

112) Malerba, M.; Gisondi, P.; Radaeli, A.; Sala, R.; Calzavara -Pinton, P.G. and Girolomoni, G.(2006):

Plasma homocysteine and folate levels in patients with chronic plaque psoriasis.
Br. J .Dermatol.; 155:1165-1169.

113) Mallbris, L.; Akre, O.; Granath, F.; Yin, L.; Lindelof, B .and Ekbom, A. (2004):

Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients.
Eur. J. Epidemiol.; 19: 225-230.

114) Mallbris, L. and McInnes, I.B. (2006):

Psoriasis is associated with lipid abnormalities at the onset of skin disease.
J .Am. Acad .Dermatol.;54: 614-621.

115) Mallon, E.; Bunce, M.; Wojnarowska, F. and Welsh, K. (1997):

HLA CW 6 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriasis.

J. Invest. Dermatol.; 109:83-89.

116) Maradit-Kremers, H.; Marian T. McEvoy, E.; Frank J.; Dann, E. and Gabriel, E.S. (2007):

Heart disease in psoriasis.

J. Am. Acad. Dermatol.; 57(2):347-354.

117) Marra, M.; Campanati, A.; Testa, R.; Sirolla, C.; Bonfigli, A.R.; Franceschi, C.; Marchegiani, F. and Offidani, A. (2007):

Effect of etanercept on insulin sensitivity in nine patients with psoriasis.

Int. J. Immunopathol. Pharmacol.; 20(4):731-736.

118) McDonald, C.J. and Calabresi, P. (1978):

Psoriasis and occlusive vascular disease.

Br. J. Dermatol.; 99: 469-475.

119) Mease, P.J.; Kivitz, A.J. and Burch, F.X. (2004):

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.

Arthritis Rheum.; 50:2264-2272.

120) Michael, P.; Schön, M.D.; Henning, W. and Boehncke, M. (2005):

Psoriasis.

N. Engl. J. Med.; 353:848-850.

121) Michael, R.L. and Alan, J.C. (2006):

Immunopathogenesis of psoriasis.

Australian J. Dermatol.; 47:151-159.

122) Moller, D.E. (2002):

Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes.

Trends Endocrinol. Metab.; 11:212-217.

123) Mrowietz, U. ; James ,T.; Elder,J. and Barker, J. (2006):

The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients.

Arch. Dermatol. Res.; 298:309-319.

124) Murphy, M. ; Kerr, P.; Jane , M. and Grant-Kels, S. (2007):

The histopathologic spectrum of psoriasis.

Clinics in Dermatology ;25: 524–528.

(N)

125) Najarian, D.J. and Gottlieb, A.B. (2003):

Connections between psoriasis and Crohn's disease.

J. Am. Acad. Dermatol.; 48:805-821.

126) Naldi, L. (1998):

Cigarette smoking and psoriasis.

Clin. Dermatol.; 16:571-574.

127) Naldi, L.; Chatenoud, L. and Linder, D. (2005):

Cigarette smoking, body mass index, and stressful life events as risk factor for psoriasis: results from an Italian case-control study.

J. Invest. Dermatol.; 125: 61-67.

128) Naldi, L.; Parazzini, F.; Brevi, A.; Peserico, A.; Fornasa, C.V. and Grosso, G. (1993):

Family history, smoking habits, alcohol consumption and risk of psoriasis.

Br. J. Dermatol.; 127: 212-217.

129) Neimann, A.L.; Shin, D.B.; Wang, X.; Margolis, D.J.; Troxel, A.B. and Gelfand, J.M. (2006):

Prevalence of cardiovascular risk factors in patients with psoriasis.

J. Am. Acad. Dermatol.; 55: 829-835.

130) Nickoloff, B.J. (1999):

Skin innate immune system in psoriasis: friend or foe [comment]?

J. Clin. Invest.; 104:1161-1164.

131) Nickoloff, B.J. and Nestle, F.O. (2004):

Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.

J. Clin. Invest.; 113:1664-1675.

132) Nijsten, T. and Wakkee, M. (2009):

Complexity of the association between psoriasis and comorbidities.

J. Invest. Dermatol.; 129:1601-1603.

(P)

133) Palacios, S. ; Casta, R. and Grazziotin, A .(2009):

Epidemiology of female sexual dysfunction

Maturitas ;63 :119–123.

134) Paus, R.; Theoharides, T.C. and Arck, P.C. (2006):

Neuroimmunoendocrine circuitry of the “brain-skin connection”.

Trends Immunol.; 27:32-39.

135) Peter, C.M.V. and Joost, S. (2008):

Clinical spectrum of psoriasis.

In: Dermatology. Second edition. Jean L Bolognia, Joseph L, Jorizzo MD,

Ronald P, Rapini MD (eds). ELSEVIER, Mosby. Volume (1); pp: 115-125.

136) Pietrzak, A .T. ; Zalewska, A.; Chodorowska, G. ; Krasowska, D.; Michalak-

Stoma,A.; Nockowski , P.; Osemlak, P.; Paszkowski, T.and Roliński, M.J.(2008):

Cytokines and anticytokines in psoriasis.

Clinica .Chimica .Acta .;394 :7–21.

137) Piper,L. (2009):

BMI linked to psoriasis onset and severity

Acta Derm .Venereol.; 89: 492–497

138) Poikolainen, K.; Karvonen, J.;and Pukkala,E.(1999):

Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis [comment].

Arch. Dermatol.;135: 1490-1493.

139) Prodanovich, S.; Ma F.; Taylor, J.R.; Pezon, F.; Fasihi, T. and Kirsner, R.S. (2005):

Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.

J .Am .Acad .Dermatol.; 52: 262-267.

140) Puig-sanz , L. (2007):

Psoriasis, a systemic disease?

Acta. Dermosifiliogr.; 98: 396-402.

(Q)

141) Qayoom, S. and Ahmad, Q.M. (2003):

Psoriasis and helicobacter pylori.

Indian J. Dermatol .Venereol.Leprol.; 69: 133-134.

(R)

142) Ragaz, A. and Ackerman, A.B. (1979):

Evolution, maturation and regression of lesions of psoriasis.

Am .J. Dermatopath.; 1:199-214.

143) Rastmanesh, R. (2009):

Psoriasis and vegetarian diets: A role for cortisol and potassium?

Med. Hypotheses; 72: 368-370.

144) Raychaudhuri, S.P. and Gross, J. (2000):

Psoriasis risk factors: role of lifestyle practices.

Cutis; 66: 348-352.

145) Reusch, J.E. (2002):

Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.

Am. J .Cardiol.; 90: 19-26.

146) Rifai, N.;Bachori, K.P. and Alber, S.(2001):

Lipids , lipoprotein and apolipoprotein .

In Tiez fundamental of clinical chemistry. Burrit CAand Ashwood ER(eds), 5th edition ,Saunder company ,USA, pp 484-489.

147) Rocha-Pereira, P.; Santos-Silva, A.; Rebelo, I.; Figueiredo, A.; Quintanilha, A .and Teixeira, F. (2001):

Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease.

Clinica .Chimica.Acta.;303:33-39.

148) Rogers, M.S. and D'Amato, R.J. (2006):

The effect of genetic diversity on angiogenesis.

Exp. Cell. Res.; 312:561-574.

149) Romano, G.; Moretti, G. and Di Benedetto, A. (1998):

Skin lesions in diabetes mellitus: prevalence and clinical correlations.

Diabetes Res .Clin. Pract.; 39:101-106.

150) Rosen, R.C.; Brown, C. and Heiman ,J.(2000):

The female sexual function index (FSFI): A Multidimensional self-report instrument for the assessment of female sexual function.

J. of Sex and Mar. Ther.; 26: 191–208.

151) Rosen, R.C. and Cappelleri, J.C.(1999):

Development and evaluation of an abridged 5 version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction.

International J. Impotence Research; 11: 319-326.

152) Rosenberg, P.; Urwitz H.; Johannesso , A.; Ros, A.M.; Lindholm, J.; Kinnman, N. and Hultcrantz, R. (2007):

Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.

J. Hepatol.; 46: 995-998.

153) Rotter, V.; Nagaev, I. and Smith, U. (2003):

Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, over expressed in human fat cells from insulin resistant subjects.

J. Biol. Chem.; 278: 45777-45784.

154) Rozanski, A.; Blumenthal, J.A.; Davidson, K.W.; Saab, P.G. and Kubzansky, L.(2005):

The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology.

J .Am. Coll. Cardiol.; 45:637-651.

155) Russo, P.A.J.; Ilchef, R. and Cooper,A.J. (2004):

Psychiatric morbidity in psoriasis: A review.

Australian J. Dermatol.; 45: 155- 161.

(S)

156) Sabat, R. ; Philipp, S.; Flich C.; Kreutzer, S.; Wallace, E.; Asadullah, K.; Volk, H. ; Sterry, W. and Wolk, K. (2007):

Immunopathogenesis of psoriasis.

J. Exp. Dermatol.; 16: 779–798.

157) Sampogna, F.; Gisondi, P.; Tabolli, S. and Abeni, D. (2006):

Impairment of sexual life in patients with psoriasis.

Dermatology; 214:144-150.

158) Sattar, N.; McCarey, D.W.; Capell, H. and McInnes, I.B. (2003):

Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis.

Circulation ;108: 2957-2963.

159) Schlaak, J.F.; Buslau, M.; Jochum, W; Hermann, E; Girndt, M. and Gallati, H. (1994):

T cells involved in psoriasis vulgaris belong to the Th1 subset.

J. Invest. Dermatol. 102:145-149.

160) Schon, M.P. and Boehncke, W.H. (2005):

Psoriasis.

N. Engl. J. Med.; 352(18):1899-1912.

161) Seckin, D.; Tokgozoglu, L. and Akkaya, S. (1994):

Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis?

J. Am. Acad. Dermatol.; 31: 445-449.

162) Senn, J.J.; Klover, P.J.; Nowak, I.A. and Mooney, R.A. (2002):

Interleukin-6 induces cellular insulin resistance in hepatocytes.

Diabetes; 102: 3391-3399.

163) Shaker, O.G.; Moustafa, W.; Essmat, S; Abdel-Halim, M. and El-Komy, M. (2006):

The role of interleukin-12 in the pathogenesis of psoriasis.

Clin. Biochem.; 39:119-125.

164) Shepherd, P.R. and Kahn, B.B. (1999):

Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus.

N .Engl. J. Med.; 341(4):248-257.

165) Shobha, S.; Rao, M.D.; Phillip, D. and Tamara, M. (2004):

Impaired Glucose Tolerance and Impaired Fasting Glucose.

J.Am .Acad. of Family Physicians; 69:1961-1972.

166) Sivitz, W.I. (2001):

Lipotoxicity and glucotoxicity in type 2 diabetes: effects on development and progression.

Postgrad. Med.; 109: 55-64.

167) Sivitz, W.I. (2004):

Understanding insulin resistance: What are the clinical implications?

Postgrad. Med.; 116: 41-48.

168) Slynkova, K. ; Mannino, D .M.; Martin, G. S.; Morehead, R. S. and Doherty, E.D. (2006):

The role of body mass index and diabetes in the development of acute organ failure and subsequent mortality in an observational cohort.

Crit . Care.; 10 : 137-140.

169) Sommer, D.M.; Jenisch, S.; Suchan, M; Christophers, E. and Weichenthal, M. (2006):

Increase prevalence of the metabolic syndrome in patients with moderate to severe psoriasis.

Arch. Dermatol. Res.; 298: 321-328.

170) Sterry, W. and Muche, J.M. (2003):

Erythroderma.

In: Dermatology. Bologna JL, Jorizzo JL, Rapini RP (eds).

First edition. Mosby. London, Edinburgh, New York, Philadelphia, St Lois, Sydney, Toronto; pp: 165-174.

171) Sterry, W.; Strober, B.E. and Menter, A. (2007):

Obesity in psoriasis: the metabolic, clinical and therapeutic implications.

Br. J. Dermatol.; 157: 649-655.

172) Steven, E.; Shoelson,H.; Lee,J.; Allison, B. and Goldfine,L.(2006):

Inflammation and insulin resistance.

J. Clin. Invest. ; 116:1793-1801.

173) Stewart, P.M. and Tomlinson,J.W. (2002):

Cortisol, 11 betahydroxysteroid dehydrogenase type 1 and central obesity.

Trends Endocrinol .Metab.; 13(3):94-96.

174) Strober, B.E. and Menon, K. (2005):

Folate supplementation during Methotrexate therapy for patients with psoriasis.
J .Am. Acad .Dermatol.; 53:652-659.

175) Strong, K.; Mathers, C.; Leeder, S. and Beaglehole, R. (2005):

Preventing chronic diseases: how many lives can we save?
Lancet ; 366: 1578-1582.

(T)

**176) Takahashi, H.; Tsuji,H.; Takahashi,I.;Hashimoto,Y.; Ishida-Yamamoto, A.
and Iizuka, H.(2008):**

Prevalence of obesity/adiposity in Japanese psoriasis patients: Adiposity is
correlated with the severity of psoriasis.
J.of Dermatological Science; 55: 74-76.

177) Taler, S.J.; Textor, S.C.; Canzanella, V.J. and Schwartz, L. (1999):

Cyclosporin-induced hypertension: incidence, pathogenesis and management.
Drug Saf.; 20:437-449.

178) Tam ,L.S.;Tomlinson, B.; Chu, T.T.; Li, M.;Leung, Y.Y.; Kwok LW;Li

TK;Yu, T.; Zhu, Y.E.; Wong, K.C.; Kun, E.W. and Li, E.K.(2007):

Cardiovascular risk profile of patients with psoriatic arthritis compared to
controls--the role of inflammation.
Rheumatology; 47:718–723.

179) Tonela,G. and Conrada,C.(2009):

Interplay between keratinocytes and immune cells—Recent insights into psoriasis
pathogenesis.

The International Journal of Biochemistry and Cell Biology; 41: 963–968.

(V)

180) Van de Kerkhof , P.C.M. (2003):

Psoriasis.

In: Dermatology. Bologna JL, Jorizzo JL, Rapini RP (eds). First edition. Mosby. London, Edinburgh, New York, Philadelphia, St Lois, Sydney, Toronto; pp: 125-149.

181) Vlachopoulos, C. ; Rokkas, K. ; Ioakeimidis, N. and Stefanadis, C. (2007):

Inflammation, metabolic Syndrome, erectile dysfunction, and coronary artery disease: Common Links.

J. Eur. assoc. urology ;52: 1590-1600.

(W)

182) Wakkee, M.; Thio, H.B.; Prens, E.P.; Sijbrands, E.J. and Neumann, H.A.(2007):

Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis; 190:1-9.

183) Wallace, T.M. and Matthews, D.R. (2002):

The assessment of insulin resistance in man.

Diabetes Med.; 19: 527-534.

184) Watson, W.; Cann , H.M.; Farber, E.M. and Nall, M.L. (1972):

The genetics of psoriasis.

Arch .Dermatol. ; 105:197-207.

185) Wexler, D.; Hu, F. and Manson, J. (2005):

Mediating effects of inflammatory biomarkers on insulin resistance associated with obesity.

Obes. Res.; 52:1772-1783.

186) Wolters, M. (2005):

Diet and psoriasis: experimental data and clinical evidence.

Br .J .Dermatol.; 153:706-714.

(Y)

187) Yawalkar, N.; Gion, G.; Tschanner, M.; Robert, E.; Hunger and Hassan,

A.S.(2009):

Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis.

J. of Dermatological Science ;54 :99–105.

188) Yazdani, B.; Thomas, M.; Hans, P.B.; Josef, H.; Winfried, G. and Thomas,

C.W. (2006):

Relapse of diabetes after interruption of chronic administration of anti–tumor necrosis factor- antibody Infliximab.

Diabetes Care; 29:1712-1713.

(Z)

189) Zheng, Y.; Danilenko, D.M.; Valdez, P.; Kasman, I .; Eastham-Anderson,

J. and Wu, J.(2007):

Interleukin-22, a (TH)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis.

Nature; 445 : 648–651.